title: [Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy].
abstract: Biochemical markers of liver fibrosis, because they can be tested noninvasively, reproducibly, and reliably, may constitute a true alternative to liver biopsies. Scores must be used only in the circumstances for which they have been validated. Scores for the Fibrotest-Actitest have been studied and validated most widely. Fibroscan, an imaging technique that uses transient elastrography to measures liver stiffness, has been validated acceptably for management of hepatitis C (HCV). General practitioners can order Fibroscan testing to assess the extent of hepatic lesions in patients with chronic HCV. Fibrotest and/or Fibroscan testing may replace liver biopsy in patients who can then receive first-or second-line treatment for HCV, regardless of genotype or transaminase levels. In the future, treatment decisions will probably rely on a combination (after validation) of these scores and on the development of genetic markers for fibrogenesis, to differentiate between patients highly likely and unlikely to develop serious fibrosis.
authors.affiliation: Laboratoire Alphabio, Marseille. philippe.halfon@alphabio.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Halfon
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.forename: Guillaume
authors.initials: G
authors.lastname: Pénaranda
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
mesh_terms: D000465:Algorithms; D001706:Biopsy; D003955:Diagnostic Tests, Routine / Q000379:methods; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000209:etiology*; D011237:Predictive Value of Tests